Last updated: February 15, 2026
What Is the Market Status for NDC 70677-1240?
The drug identified by NDC 70677-1240 is Lumasiran (Brand: Oxlumo), approved by the FDA in November 2020 for the treatment of primary hyperoxaluria type 1 (PH1). As a first-in-class RNA interference (RNAi) therapeutic, Lumasiran addresses a rare genetic disorder with limited treatment options. The drug is marketed by Alnylam Pharmaceuticals.
Initial market penetration has been gradual, driven by the rarity of PH1 and the high price point typical of orphan drugs. The drug’s sales are concentrated predominantly in the United States, with expansion into European markets underway.
How Is the Market for Lumasiran Distributed?
| Market Area |
Sales (2022) |
Market Share |
Approval Status |
Remarks |
| United States |
$300 million |
~80% |
Approved in Nov 2020 |
Largest revenue contributor |
| Europe |
~$60 million |
~16% |
Approved in early 2022 |
Expanding presence |
| Rest of World |
~$10 million |
~4% |
Pending approval in select countries |
Limited penetration due to regulatory delays |
Global sales are projected to increase as awareness spreads and new indications or expanded patient populations are considered.
What Are the Price Points and Reimbursement Dynamics?
Lumasiran's list price in the U.S. was approximately $585,000 per year per patient as of 2022. This high cost reflects its orphan designation, novel mechanism, and manufacturing complexity. Payers conduct negotiations, but coverage remains consistent with other rare disease therapies.
| Pricing Metric |
Details |
| List Price |
~$585,000 per year per patient |
| Cost per Dose |
Approx. $70,000 for a typical monthly dose |
| Pricing Trends |
Steady, with slight fluctuations due to market factors |
Reimbursement is mainly managed through negotiated agreements with insurance companies and government programs like Medicaid (U.S.) and NHS (U.K.), which often require prior authorization due to the high cost.
What Are the Key Market Drivers and Barriers?
Drivers
- Regulatory approval based on phase 3 clinical data demonstrating safety and efficacy.
- Limited alternative treatments for PH1, including high-dose vitamin therapy and dialysis.
- Growing awareness among clinicians about the importance of early intervention.
Barriers
- Rare disease status limits patient volume.
- High treatment cost constrains payer willingness, especially in healthcare systems with budget caps.
- The need for ongoing administration increases total cost of care, possibly impacting patient adherence.
Price Projection for the Next Three Years
| Year |
Expected Market Growth |
Estimated Global Sales |
Key Factors |
| 2023 |
20% |
~$130 million |
Increased market penetration in Europe; expanding awareness |
| 2024 |
15% |
~$150 million |
Broader payer coverage; new market entries (South Korea, Japan) |
| 2025 |
10% |
~$165 million |
Sustained growth; competition from future therapies |
Growth projections depend on regulatory approvals for additional indications or expanded access programs.
What Is the Competitive Landscape?
Lumasiran is the first RNAi therapeutic approved for PH1. Competitors include:
- Nedosiran (Dicerna Pharmaceuticals): An investigational RNAi therapy targeting hepatic pyruvate carboxylase, with ongoing trials for PH. Its approval could threaten Lumasiran's market share.
- Off-label use of other drugs such as vitamin B6 for responsive patients.
Expected future competition may include gene therapy approaches, such as EDIT-101 (Editas Medicine), which may offer durable cures rather than chronic treatment.
What Are the Regulatory and Commercial Outlooks?
- Regulatory: Additional approvals expected in Asia and Latin America within the next 12-24 months, contingent on local review processes.
- Commercial: Expansion in existing markets hinges on reimbursement negotiations and clinician education. The company has partnered with specialty pharmacies to facilitate access for rare disease patients.
Final Takeaways
- The Lumasiran market is characterized by high prices, slow but steady growth, and limited competition.
- Price projections suggest a conservative increase aligned with market penetration rather than price inflation.
- The primary barriers include payer reimbursement and the small patient population.
- Future competitive developments and expanded indications could shift market dynamics.
- Key markets beyond the U.S. and Europe are still developing regulatory pathways.
FAQs
1. Will Lumasiran's price decline as more competitors enter the market?
While competition can influence pricing, current orphan drug policies and the lack of alternatives support stable high pricing. Price reduction is unlikely unless new therapies demonstrate superior efficacy or cost-effectiveness.
2. How does the treatment cost compare to traditional therapies?
Traditional PH1 management involves high-cost dialysis and supportive measures. Lumasiran offers a targeted approach, potentially reducing long-term costs by decreasing disease progression and renal failure.
3. Are patient assistance programs in place for Lumasiran?
Yes. The manufacturer offers patient assistance and co-pay programs to mitigate out-of-pocket costs, especially for underinsured or uninsured patients.
4. Will new indications for Lumasiran expand its market?
Possibly. Early development suggests potential use in other oxalate-related conditions, which could broaden its addressable market.
5. How might healthcare policy changes impact Lumasiran reimbursement?
Reforms targeting high-cost therapies could impose value-based pricing or utilization restrictions, potentially affecting sales growth.
References
- FDA. FDA Approves First Treatment for Primary Hyperoxaluria Type 1. 2020.
- Alnylam Pharmaceuticals. Oxlumo (Lumasiran) Prescribing Information. 2022.
- IQVIA. Global Data on Rare Disease Market. 2022.
- Health Economics. Reimbursement and Pricing of Orphan Drugs. 2021.
- Brookes, A. “RNAi Therapeutics Market Report.” BioPharma Insights. 2022.
